No Data
Sinolink Securities: Medical industry sentiment in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.
In the third quarter, due to internal adjustments in the medical sector, changes in the overall consumer environment, and some medical insurance cost control policies still being implemented, the Q3 financial report continues to explore the bottom line of the business climate, with a recovery slower than expected.
xiamen amoytop biotech (688278): Maintaining high profit growth in Q3 24, increasing depth in the hepatitis B field.
Event: On October 24, 2024, xiamen amoytop biotech announced its third-quarter performance in 2024, achieving revenue of 1.955 billion yuan, a year-on-year increase of +33.90%; net income attributable to the parent company was 0.554 billion yuan, a year-on-year increase of +50.
Xiamen Amoytop Biotech Q3 Profit Up 50%, Revenue Rises 38%
Xiamen Amoytop Biotech (688278): Accelerating the cure for chronic hepatitis B, company performance continues to exceed expectations.
Performance Summary On October 24, 2024, the company released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 1.955 billion yuan, a year-on-year increase of +34%; Achieved a net income of 0.554 billion yuan attributable to the parent company.
Xiamen Amoytop Biotech (688278): Pegasus continues to rapidly increase in volume, further improving profit margins.
Xiamen Amoytop Biotech released the third quarter report for 2024, achieving revenue of 1.95 billion yuan in Q1-Q3 2024, an increase of 34% year-on-year; net income attributable to parent company of 0.55 billion yuan, an increase of 50% year-on-year; non-net profit attributable to parent company 5 billion yuan.
Tebao Biotech: Third quarter report 2024
No Data
No Data